Clinical Trial Update: A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating the safety and tolerability of TransCon IL-2 β/γ alone or in combination with pembrolizumab an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TransCon IL-2 β/γ
• TransCon TLR7/8 Agonist

Snippet

Sponsor: Ascendis Pharma Oncology Division A/S | Conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING